CN111436608A - 一种改善肝功能损伤的组合物及其应用 - Google Patents
一种改善肝功能损伤的组合物及其应用 Download PDFInfo
- Publication number
- CN111436608A CN111436608A CN202010315222.8A CN202010315222A CN111436608A CN 111436608 A CN111436608 A CN 111436608A CN 202010315222 A CN202010315222 A CN 202010315222A CN 111436608 A CN111436608 A CN 111436608A
- Authority
- CN
- China
- Prior art keywords
- sweetener
- composition
- compound
- liver
- fructo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 59
- 230000003908 liver function Effects 0.000 title claims abstract description 24
- 230000006378 damage Effects 0.000 title abstract description 15
- 241000207199 Citrus Species 0.000 claims abstract description 37
- 239000008122 artificial sweetener Substances 0.000 claims abstract description 37
- 235000021311 artificial sweeteners Nutrition 0.000 claims abstract description 37
- 235000020971 citrus fruits Nutrition 0.000 claims abstract description 37
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims abstract description 29
- 229940107187 fructooligosaccharide Drugs 0.000 claims abstract description 27
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims abstract description 21
- 239000000835 fiber Substances 0.000 claims abstract description 21
- 229930003944 flavone Natural products 0.000 claims abstract description 21
- 150000002212 flavone derivatives Chemical class 0.000 claims abstract description 21
- 235000011949 flavones Nutrition 0.000 claims abstract description 21
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000004376 Sucralose Substances 0.000 claims abstract description 10
- 235000019408 sucralose Nutrition 0.000 claims abstract description 10
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims abstract description 10
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims abstract description 6
- 235000019204 saccharin Nutrition 0.000 claims abstract description 6
- 229940081974 saccharin Drugs 0.000 claims abstract description 6
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 claims abstract description 6
- 239000003765 sweetening agent Substances 0.000 claims description 66
- 235000003599 food sweetener Nutrition 0.000 claims description 65
- 150000001875 compounds Chemical class 0.000 claims description 59
- 235000021096 natural sweeteners Nutrition 0.000 claims description 19
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 9
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 7
- 229930091371 Fructose Natural products 0.000 claims description 7
- 239000005715 Fructose Substances 0.000 claims description 7
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 7
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 7
- 235000019202 steviosides Nutrition 0.000 claims description 7
- 206010019670 Hepatic function abnormal Diseases 0.000 claims description 6
- 229920002670 Fructan Polymers 0.000 claims description 4
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 4
- 230000006735 deficit Effects 0.000 claims description 4
- 108010011485 Aspartame Proteins 0.000 claims description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 2
- 239000000605 aspartame Substances 0.000 claims description 2
- 235000010357 aspartame Nutrition 0.000 claims description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 2
- 229960003438 aspartame Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229940013618 stevioside Drugs 0.000 claims description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000004185 liver Anatomy 0.000 abstract description 18
- 208000027418 Wounds and injury Diseases 0.000 abstract description 6
- 208000014674 injury Diseases 0.000 abstract description 6
- 208000006454 hepatitis Diseases 0.000 abstract description 4
- 230000007774 longterm Effects 0.000 abstract description 4
- 239000002158 endotoxin Substances 0.000 abstract description 3
- 229920006008 lipopolysaccharide Polymers 0.000 abstract description 3
- 208000018191 liver inflammation Diseases 0.000 abstract description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 abstract description 2
- 108010082126 Alanine transaminase Proteins 0.000 abstract description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 abstract description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 abstract description 2
- 102000004889 Interleukin-6 Human genes 0.000 abstract description 2
- 108090001005 Interleukin-6 Proteins 0.000 abstract description 2
- 230000001580 bacterial effect Effects 0.000 abstract description 2
- 229940100601 interleukin-6 Drugs 0.000 abstract description 2
- 239000005550 inflammation mediator Substances 0.000 abstract 1
- 238000001035 drying Methods 0.000 description 41
- 239000000243 solution Substances 0.000 description 24
- 230000000694 effects Effects 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 20
- 108020004999 messenger RNA Proteins 0.000 description 14
- 238000010438 heat treatment Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 8
- 235000013305 food Nutrition 0.000 description 7
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000004383 Steviol glycoside Substances 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 235000019411 steviol glycoside Nutrition 0.000 description 5
- 229930182488 steviol glycoside Natural products 0.000 description 5
- 150000008144 steviol glycosides Chemical class 0.000 description 5
- 239000001329 FEMA 3811 Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- ITVGXXMINPYUHD-CUVHLRMHSA-N neohesperidin dihydrochalcone Chemical compound C1=C(O)C(OC)=CC=C1CCC(=O)C(C(=C1)O)=C(O)C=C1O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ITVGXXMINPYUHD-CUVHLRMHSA-N 0.000 description 4
- 229940089953 neohesperidin dihydrochalcone Drugs 0.000 description 4
- 235000010434 neohesperidine DC Nutrition 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 3
- QGGZBXOADPVUPN-UHFFFAOYSA-N dihydrochalcone Chemical compound C=1C=CC=CC=1C(=O)CCC1=CC=CC=C1 QGGZBXOADPVUPN-UHFFFAOYSA-N 0.000 description 3
- PXLWOFBAEVGBOA-UHFFFAOYSA-N dihydrochalcone Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C=CC(C(=O)CC(O)C=2C=CC(O)=CC=2)=C1O PXLWOFBAEVGBOA-UHFFFAOYSA-N 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000005228 liver tissue Anatomy 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241001678559 COVID-19 virus Species 0.000 description 2
- 239000001183 FEMA 4495 Substances 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- CWBZAESOUBENAP-QVNVHUMTSA-N Naringin dihydrochalcone Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C(O)C(C(=O)CCC=3C=CC(O)=CC=3)=C(O)C=2)O[C@H](CO)[C@@H](O)[C@@H]1O CWBZAESOUBENAP-QVNVHUMTSA-N 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000001689 FEMA 4674 Substances 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930182647 Trilobatin Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000004280 healthy diet Nutrition 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000004609 intestinal homeostasis Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 235000021092 sugar substitutes Nutrition 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- GSTCPEBQYSOEHV-QNDFHXLGSA-N trilobatin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C=C1O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 GSTCPEBQYSOEHV-QNDFHXLGSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/30—Artificial sweetening agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/30—Artificial sweetening agents
- A23L27/33—Artificial sweetening agents containing sugars or derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供了一种改善肝功能损伤的组合物及其应用,所述组合物的组分包括:柑橘黄酮、柑橘纤维和低聚果糖。所述组合物中的柑橘黄酮、柑橘纤维和低聚果糖组合使用具有降低肝脏中谷丙转氨酶(ALT)和碱性磷酸酶(ALP)含量的作用,还能够降低肝脏中炎症介质因子细菌脂多糖(LPS)和白细胞介素‑6(IL‑6)的含量,能够改善ALT、ALP、LPS、IL‑6中至少一种含量的升高的肝功能损伤,能够治疗或改善长期食用人工甜味剂如三氯蔗糖或糖精引起的肝脏炎症。
Description
技术领域
本发明涉及保健制品技术领域,具体涉及一种改善肝功能损伤的组合物及其应用。
背景技术
人工甜味剂主要是指一些具有甜味但不是糖类的化学物质,甜度一般比蔗糖高10倍至数百倍,目前被用作代糖广泛应用在蛋糕,饮料等食品中。但是人工甜味剂和糖一样吃多了都会对身体健康造成一定的影响,特别是会扰乱人体糖代谢,引发肝脏炎症,损害肝脏功能等。
柑橘黄酮为天然的植物黄酮,近年研究发现它的多种药用作用,包括抗氧化、抗肿瘤、抗炎、降脂、降血糖、对心血管系统的作用和对神经系统、免疫系统的作用。
低聚果糖是一种天然活性物质,它能明显改善肠道内微生物菌群比例。它是肠内双歧杆菌的活化增殖因子,可减少和抑制肠内腐败物质的产生,抑制有害细菌的生长,调节肠道内平衡,能促进微量元素钙、铁的吸收和利用,以防止骨质疏松症,也可以减少肝脏的毒素。
柑橘纤维能够增加肠道及胃内的食物体积,可增加饱足感;又能促进肠胃蠕动,可舒解便秘;同时膳食纤维也能吸附肠道中的有害物质以便排出;改善肠道菌群,为益生菌的增殖提供能量和营养。膳食纤维是健康饮食不可缺少的,纤维在保持消化系统健康上扮演着重要的角色,同时摄取足够的纤维也可以预防心血管疾病、癌症、糖尿病以及其它疾病。
根据现有问题,研制一种能够改善肝功能损伤的组合物成为急需解决的问题。
发明内容
本发明公开的目的是提供一种组合物,使得所述组合物具有改善人体肝功能损伤的功效。
为实现上述目的,技术方案如下:
一种组合物,所述组合物的组分包括:柑橘黄酮、柑橘纤维和低聚果糖。
按质量份数计,所述组合物包括:柑橘黄酮1-100份、柑橘纤维1-100份和低聚果糖1-100份。
所述的组合物在改善肝功能损伤中的应用。
所述肝功能损伤包括ALT、 ALP、LPS、IL-6中至少一种含量的升高。
一种复配甜味剂,所述复配甜味剂包括:橘黄酮、柑橘纤维和低聚果糖。
所述复配甜味剂还包括:人工甜味剂和天然甜味剂。
所述人工甜味剂与所述组合物添加的质量比为(40-90):1,所述天然甜味剂与所述人工甜味剂添加的质量比为(5-60):1。
所述人工甜味剂为阿斯巴甜、三氯蔗糖或糖精的任意一种。
所述天然甜味剂为二氢查尔酮类、甜菊糖苷、海藻糖、阿拉伯糖、果糖、果聚糖中的一种或多种。
所述二氢查尔酮类为新甲基橙皮苷二氢查耳酮、柚苷二氢查耳酮、三叶苷中的一种或多种。
所述复配甜味剂在制备改善肝功能损伤药物中的应用。
一种复配甜味剂的制备方法,所述制备方法的具体步骤为:将人工甜味剂,柑橘黄酮、柑橘纤维和低聚果糖组合物,和天然甜味剂混匀,然后溶于水,得到复配甜味剂溶液;然后进行对得到的复配甜味剂溶液进行干燥。
所述干燥的方法为喷雾干燥或冷冻干燥;优选地所述喷雾干燥中在复配甜味剂溶液中按照(1-15):1的比例加入助干剂,所述喷雾干燥的条件为:入料浓度为5%-50%,入料流量为1-100L/min,入料温度为30-75℃,进风温度为80-200℃,喷头转速为10000-35000 r/min。
所述冷冻干燥的具体操作为:
(1)将复配甜味剂溶液在-30℃下预冷至复配甜味剂溶液中的水分充分冻结;
(2)冷冻后的复配甜味剂溶液进行真空恒温干燥,真空度为5-50Pa,温度为-30-10℃,干燥2-10小时;
(3)将真空恒温干燥后的复配甜味剂溶液进行真空加热干燥,条件为温度35 -40℃干燥20-30min,然后升温至55-75℃并干燥1-2小时,真空度为10- 40Pa;
(4)将真空加热干燥后的复配甜味剂进行真空降温干燥,条件为温度降温至35-40℃并维持1-2 小时,真空度为10 -30Pa,最后得到复配甜味剂。
本申请公开的有益效果是:提供了一种组合物,所述组合物中的柑橘黄酮、柑橘纤维和低聚果糖组合使用具有降低肝脏中谷丙转氨酶(ALT)和碱性磷酸酶(ALP)含量的作用,还能够降低肝脏中炎症介质因子细菌脂多糖(LPS)和白细胞介素-6(IL-6)的含量,能够改善ALT、 ALP、LPS、IL-6中至少一种含量的升高的肝功能损伤,能够治疗或改善长期食用人工甜味剂如三氯蔗糖或糖精引起的肝脏炎症。
利用本发明所述组合物柑橘黄酮、柑橘纤维和低聚果糖所制备的复配甜味剂,不仅能够消除甜味剂中人工甜味剂对肝功能带来的损伤,而且能够强化肝脏,这样使得复配甜味剂不仅能够满足人们所需要的口感,而且具有一定的保健作用,可将复配甜味剂应用到改善肝功能损伤药片的制备中。
附图说明
图1为本发明所述组合物对患有肝功能损伤小鼠体内中的ALT含量影响检测结果图。
图2为本发明所述组合物对患有肝功能损伤小鼠体内中的ALP含量影响检测结果图。
图3为本发明所述组合物对患有肝功能损伤小鼠体内中的LPS含量影响检测结果图。
图4为本发明所述组合物对患有肝功能损伤小鼠体内中的Liver-IL-6 mRNA表达量影响检测结果图。
图5为本发明所述复配甜味剂对小鼠肝功能ALT含量影响的检测结果图。
图6为本发明所述复配甜味剂对小鼠肝功能ALP含量影响的检测结果图。
图7为本发明所述复配甜味剂对小鼠血液LPS含量影响的检测结果图。
图8为本发明所述复配甜味剂对小鼠Liver-IL-6 mRNA表达量影响的检测结果图。
本发明图片中,*示存在显著性差异,p<0.05;**示存在极显著性差异,p<0.01;***示存在极显著性差异,p<0.001。
具体实施方式
以下各步骤仅用以说明本发明的技术方案,而非对其限制;尽管参照前述各步骤对本发明进行了详细的说明,但本领域的普通技术人员应当理解:其依然可以对前述各步骤所记载的技术方案进行修改,或者对其中部分或者全部技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本发明各步骤技术方案的范围。
实施例1
一种组合物,所述组合物各组分及添加的质量份数分别为:柑橘黄酮1份、柑橘纤维1份和低聚果糖1份。
实施例2
一种组合物,所述组合物各组分及添加的质量份数分别为:柑橘黄酮100份、柑橘纤维100份和低聚果糖100份。
实施例3
一种组合物,所述组合物各组分及添加的质量份数分别为:柑橘黄酮50份、柑橘纤维35份和低聚果糖60份。
对以上实施例做进一步的效果检测。
50只6周大的以三氯蔗糖喂养的具有相似程度肝炎的雌性C57BL/6小鼠,分成五组(n = 10),在武汉病毒所动物房进行为期10周的动物实验,饲养条件为SPF级,12h光照黑暗循环,室温保持在22±1℃,湿度为40-60%,分组情况为:a为实施例1组(正常食物和50mg/mL实施例1所述组合物的灭菌水溶液),b空白对照组(正常食物和灭菌水),c为实施例2组(正常食物和50mg/mL实施例2所述组合物的灭菌水溶液),d为低聚果糖组(正常食物和50mg/mL低聚果糖的灭菌水溶液),e为实施例3组(正常食物和50 mg/mL实施例3所述组合物的灭菌水溶液),分别按照分组分别处理小鼠,在喂养10周后利用全自动生化分析仪对小鼠肝功能ALT和ALP的含量进行检测,利用Elise试剂盒对炎症介质因子细菌脂多糖LPS和Liver-IL-6mRNA(肝组织白细胞介素-6 mRNA)的表达进行检测。
检测设备:Elise试剂盒购买自博士德生物工程有限公司(Boster,中国),血生化检测于Chemray240全自动生化分析仪(深圳雷社生命科技,中国)上完成。
小鼠肝功能ALT含量的检测结果如图1(a为实施例1组;b为空白对照组;c为实施例2组;d为低聚果糖组;e为实施例3组)所示,可以看出与空白对照组相比较而言,低聚果糖能够一定程度上降低小鼠肝脏中ALT的含量,具有改善肝功能损伤的效果,但是实施例1、实施例2和实施例3中所述的组合物:柑橘黄酮、柑橘纤维和低聚果糖,也能够降低小鼠肝脏中ALT的含量,且作用效果要高于低聚果糖,因此可以看出柑橘黄酮、柑橘纤维与低聚果糖组合对降低肝脏中ALT的含量具有更好的效果。
小鼠肝功能ALP含量的检测结果如图2(a为实施例1组;b为空白对照组;c为实施例2组;d为低聚果糖组;e为实施例3组)所示,可以看出与空白对照组相比较而言低聚果糖能够一定程度上降低小鼠肝脏中ALP的含量,但是实施例1、实施例2和实施例3中所述的组合物:柑橘黄酮、柑橘纤维和低聚果糖,也能够降低小鼠肝脏中ALP的含量,且作用效果要高于低聚果糖,因此可以看出柑橘黄酮、柑橘纤维与低聚果糖组合对降低肝脏中ALP的含量具有更好的效果。
小鼠肝功能LPS和Liver-IL-6 mRNA表达量的检测结果如图3(a为实施例1组;b为空白对照组;c为实施例2组;d为低聚果糖组;e为实施例3组)和图4(a为实施例1组;b为空白对照组;c为实施例2组;d为低聚果糖组;e为实施例3组)所示,可以看出与空白对照组相比较而言,低聚果糖具有降低肝脏中LPS和Liver-IL-6 mRNA表达量的作用,但是实施例1、实施例2和实施例3中所述的组合物:柑橘黄酮、柑橘纤维和低聚果糖对肝脏中LPS和Liver-IL-6 mRNA表达量的降低效果明显高于低聚果糖单独的作用效果,其中Liver-IL-6 mRNA表达量的降低表明肝组织中IL-6含量的降低。
肝组织中ALT、ALP、LPS、 IL-6含量升高,代表肝功能达到了一定的损伤,本发明公开的组合物,能够降低肝组织中ALT和ALP的含量,且能够降低肝组织中LPS的含量和Liver-IL-6 mRNA的表达量,因此本发明公开的组合物,能够治疗或改善ALT、 ALP、LPS、IL-6中至少一种含量的升高的肝功能损伤,例如长期食用人工甜味剂如三氯蔗糖或糖精引起的肝脏炎症。
实施例5
一种复配甜味剂,所述复配甜味剂是由人工甜味剂、实施例1所述组合物和天然甜味剂三种组分组成,其中所述人工甜味剂为:三氯蔗糖;所述天然甜味剂为:柚苷二氢查耳酮、甜菊糖苷、海藻糖、阿拉伯糖、果糖和果聚糖的混合物。
其中所述人工甜味剂与实施例1所述组合物添加的质量比为40:1;所述天然甜味剂与所述人工甜味剂添加的质量比为5:1。
一种复配甜味剂的制备方法,所述制备方法的具体步骤为:按照上述添加比例,将人工甜味剂、实施例1所述组合物和天然甜味剂混匀,然后溶于水,得到复配甜味剂溶液;然后进行对得到的复配甜味剂溶液进行干燥,所述干燥的方法为冷冻干燥,具体操作为:
(1)将复配甜味剂溶液在-30℃下预冷2小时,直至复配甜味剂溶液中的水分充分冻结;
(2)真空恒温干燥:将冷冻后的复配甜味剂溶液迅速放入冻干机的干燥仓内,开始抽真空直至干燥仓内真空度维持在50Pa,保持干燥仓内温度维持在-20℃,干燥10小时;
(3)真空加热干燥:干燥仓内加热板进行加热,直至干燥仓内温度达35℃并维持30min,然后升温至75℃并维持1小时,干燥仓内真空度维持在40Pa;
(4)真空降温干燥:对干燥仓内温度进行调控,将干燥仓内温度降温至40℃并维持1小时,干燥仓内真空度维持在30Pa,得到复配甜味剂。
实施例6
一种复配甜味剂,所述复配甜味剂是由人工甜味剂、实施例2所述组合物和天然甜味剂三种组分组成,其中所述人工甜味剂为:糖精;所述天然甜味剂为:新甲基橙皮苷二氢查耳酮、甜菊糖苷、海藻糖、阿拉伯糖、果糖和果聚糖的混合物。
所述人工甜味剂与实施例2所述组合物添加的质量比为60:1;所述天然甜味剂与所述人工甜味剂添加的质量比为25:1。
一种复配甜味剂的制备方法,所述制备方法的具体步骤为:按照上述添加比例,将人工甜味剂、实施例2所述组合物和天然甜味剂混匀,然后溶于水,得到复配甜味剂溶液;然后对得到的复配甜味剂溶液进行冷冻干燥,冷冻干燥的具体操作为:
(1)将复配甜味剂溶液在-30℃下预冷2小时,直至复配甜味剂溶液中的水分充分冻结;
(2)真空恒温干燥:将冷冻后的复配甜味剂溶液迅速放入冻干机的干燥仓内,开始抽真空直至干燥仓内真空度维持在30Pa,保持干燥仓内温度维持在-25℃之间,干燥6小时;
(3)真空加热干燥:干燥仓内加热板进行加热,直至干燥仓内温度达到 40℃并维持30min,然后升温至75℃并维持2小时,干燥仓内真空度维持在 40Pa;
(4)真空降温干燥:对干燥仓内温度进行调控,将干燥仓内温度降温至 40℃并维持2小时,干燥仓内真空度维持在30Pa,最后得到复配甜味剂。
实施例7
一种复配甜味剂,所述复配甜味剂是由人工甜味剂、实施例3所述组合物和天然甜味剂三种组分组成,其中所述人工甜味剂为:三氯蔗糖;所述天然甜味剂为:新甲基橙皮苷二氢查耳酮、甜菊糖苷、海藻糖和果糖的混合物。
其中人工甜味剂与实施例3所述组合物添加的质量比为1:60;所述天然甜味剂与所述人工甜味剂添加的质量比为100:1。
一种复配甜味剂的制备方法,所述制备方法的具体步骤为:按照上述添加比例,将人工甜味剂、实施例3所述组合物和天然甜味剂混匀,然后溶于水,得到复配甜味剂溶液;然后进行对得到的复配甜味剂溶液进行干燥,所述干燥的方法为喷雾干燥,利用离心式喷雾干燥机,干燥条件为,复配甜味剂溶液:助干剂=10:1,入料浓16%,入料流量20L/min,入料温度50℃,进风温度156℃,喷头转速25000r/min,最后得到复配甜味剂。
对比例
甜味剂由两种组分组成,其中一种组分为:三氯蔗糖;另一组分的成分包括:新甲基橙皮苷二氢查耳酮、甜菊糖苷、海藻糖和果糖的混合物;按照上述实施例7中三氯蔗糖、新甲基橙皮苷二氢查耳酮、甜菊糖苷、海藻糖和果糖的添加量进行制备。
一种甜味剂制备方法,所述制备方法的具体步骤为:按照上述添加比例,将两种组分混匀,然后溶于水,得到复配甜味剂溶液;然后进行对得到的复配甜味剂溶液进行干燥,所述干燥的方法为喷雾干燥,利用离心式喷雾干燥机,干燥条件为,复配甜味剂溶液:助干剂=10:1,入料浓度16%,入料流量20L/min,入料温度50℃,进风温度156℃,喷头转速25000r/min,最后得到复配甜味剂。
对以上实施例做进一步的效果检测。
50只6周大的雌性C57BL/6小鼠,分成五组 (n = 10),在武汉病毒所动物房进行为期10周的动物实验,饲养条件为SPF级,12h光照黑暗循环,室温保持在22±1℃,湿度为40-60%,分别将实施例5、实施例6、实施例7所制备的复配甜味剂和对比例中所制备的甜味剂,以50mg/mL浓度喂养给小鼠,然后设置空白对照喂养相同量的灭菌水,在喂养10周后利用全自动生化分析仪对小鼠肝功能ALT和ALP的含量进行检测,利用Elise试剂盒对炎症介质因子细菌脂多糖LPS和Liver-IL-6 mRNA的表达进行检测。
检测设备:Elise试剂盒购买自博士德生物工程有限公司(Boster,中国),血生化检测于Chemray240全自动生化分析仪(深圳雷社生命科技,中国)上完成。
小鼠肝功能ALT和ALP含量的检测结果如图5和图6所示,可以看出实施例5、实施例6、实施例7所制备的复配甜味剂与空白对照组相比ALT和ALP含量相差不大,而与对比例相比有较大的差异,因此将本发明所述组合物应用到复配甜味剂中,可以抵消掉人工甜味剂对肝脏的损害;进而说明长期服用本发明所述的复配甜味剂不会造成肝损伤。
小鼠血液中LPS和Liver-IL-6 mRNA表达量的检测结果如图7和图8所示,可以看出实施例5、实施例6、实施例7所制备的复配甜味剂与空白对照组相比较而言,小鼠血液中LPS的含量以及Liver-IL-6 mRNA表达量相当或者稍微降低,而与对比例相比有较大差异,其中Liver-IL-6 mRNA表达量的降低表明IL-6含量降低,说明将本发明所述组合物应用到复配甜味剂中可以抵消掉人工甜味剂对小鼠血液中LPS的含量以及Liver-IL-6 mRNA表达量的增高,从而使得在食用复配甜味剂时无副作用。
因此本发明所述组合物应用到复配甜味剂中,不仅能够消除甜味剂中人工甜味剂对肝功能带来的损伤,而且能够强化肝脏,这样使得复配甜味剂不仅能够满足人们所需要的口感,而且具有一定的保健作用。
Claims (10)
1.一种组合物,其特征在于,所述组合物的组分包括:柑橘黄酮、柑橘纤维和低聚果糖。
2.根据权利要求1中所述的组合物,其特征在于,按质量份数计,所述组合物包括:柑橘黄酮1-100份、柑橘纤维1-100份和低聚果糖1-100份。
3.如权利要求1或2中所述的组合物在改善肝功能损伤中的应用。
4.根据权利要求3中所述的应用,其特征在于,所述肝功能损伤包括ALT、 ALP、LPS、IL-6中至少一种含量的升高。
5.一种复配甜味剂,其特征在于,所述复配甜味剂包括:权利要求1或2所述的组合物。
6.根据权利要求5中所述的复配甜味剂,其特征在于,所述复配甜味剂还包括:人工甜味剂和天然甜味剂。
7.根据权利要求6中所述的复配甜味剂,其特征在于,所述人工甜味剂与所述组合物添加的质量比为(40-90):1,所述天然甜味剂与所述人工甜味剂添加的质量比为(5-60):1。
8.根据权利要求6中所述的复配甜味剂,其特征在于,所述人工甜味剂为阿斯巴甜、三氯蔗糖或糖精的任意一种。
9.根据权利要求6中所述的复配甜味剂,其特征在于,所述天然甜味剂为二氢查尔酮类、甜菊糖苷、海藻糖、阿拉伯糖、果糖、果聚糖中的一种或多种。
10.如权利要求5-9任意一项所述的复配甜味剂在制备改善肝功能损伤药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010315222.8A CN111436608A (zh) | 2020-04-21 | 2020-04-21 | 一种改善肝功能损伤的组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010315222.8A CN111436608A (zh) | 2020-04-21 | 2020-04-21 | 一种改善肝功能损伤的组合物及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111436608A true CN111436608A (zh) | 2020-07-24 |
Family
ID=71653521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010315222.8A Pending CN111436608A (zh) | 2020-04-21 | 2020-04-21 | 一种改善肝功能损伤的组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111436608A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023019461A1 (zh) * | 2021-08-18 | 2023-02-23 | 梅州金柚康健康科技有限公司 | 一种改善肝功能损伤的组合物及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20000000751A (ko) * | 1998-06-03 | 2000-01-15 | 박호군 | 감귤류 과피 유래 바이오플라보노이드를 포함하는 간기능 보호작용이 있는 알콜성 음료 조성물 |
CN105475799A (zh) * | 2016-01-05 | 2016-04-13 | 安徽宇宁生物科技有限公司 | 一种柑橘类黄酮活性饮料及其制备方法 |
WO2016153211A2 (ko) * | 2015-03-20 | 2016-09-29 | 주식회사 뉴트라팜텍 | 감귤류 과피 추출물의 제조방법 및 간 손상 예방, 개선 또는 치료용 조성물 |
CN108619283A (zh) * | 2017-03-17 | 2018-10-09 | 亚宝药业集团股份有限公司 | 一种用于改善脂质代谢、减少内脏脂肪的组合物 |
-
2020
- 2020-04-21 CN CN202010315222.8A patent/CN111436608A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20000000751A (ko) * | 1998-06-03 | 2000-01-15 | 박호군 | 감귤류 과피 유래 바이오플라보노이드를 포함하는 간기능 보호작용이 있는 알콜성 음료 조성물 |
WO2016153211A2 (ko) * | 2015-03-20 | 2016-09-29 | 주식회사 뉴트라팜텍 | 감귤류 과피 추출물의 제조방법 및 간 손상 예방, 개선 또는 치료용 조성물 |
CN105475799A (zh) * | 2016-01-05 | 2016-04-13 | 安徽宇宁生物科技有限公司 | 一种柑橘类黄酮活性饮料及其制备方法 |
CN108619283A (zh) * | 2017-03-17 | 2018-10-09 | 亚宝药业集团股份有限公司 | 一种用于改善脂质代谢、减少内脏脂肪的组合物 |
Non-Patent Citations (4)
Title |
---|
刘蕊等: "柑橘属黄酮类化合物橙皮苷和橙皮素的抗氧化和抗炎特性分子机制综述", 《中国医药导刊》 * |
杨其蒕: "《天然药物化学》", 31 January 2003, 中国医药科技出版社 * |
黄睿等: "柑橘类黄酮的生物学活性及提高生物利用度技术研究进展", 《食品科学》 * |
龚子恒等: "橙皮苷对D- 氨基半乳糖小鼠急性肝损伤氧化应激的影响", 《长江大学学报》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023019461A1 (zh) * | 2021-08-18 | 2023-02-23 | 梅州金柚康健康科技有限公司 | 一种改善肝功能损伤的组合物及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Di Bartolomeo et al. | Prebiotics to fight diseases: reality or fiction? | |
Jiang et al. | Effect of Durio zibethinus rind polysaccharide on functional constipation and intestinal microbiota in rats | |
Lu et al. | Neohesperidin attenuates obesity by altering the composition of the gut microbiota in high‐fat diet‐fed mice | |
Rose et al. | Influence of dietary fiber on inflammatory bowel disease and colon cancer: importance of fermentation pattern | |
US9364538B2 (en) | Compositions containing mixtures of fermentable fibers | |
CN101772308B (zh) | 益生菌和纤维在腹泻上的应用 | |
Qin et al. | Inulin: Properties and health benefits | |
Du et al. | Recent progress in biological activities and health benefits of konjac glucomannan and its derivatives | |
JP2010120945A (ja) | 栄養性の改良されたイヌリン製品 | |
CN110636760B (zh) | 肠道健康促进组合物 | |
BRPI0611020A2 (pt) | uso de polidextrose para estimular os atributos funcionais de oligossacarìdeos do leite humano em crianças pequenas alimentadas com fórmula | |
WO2008091170A1 (en) | A preparation containing sodium butyrate and the application of a preparation containing sodium butyrate | |
EP1661574A1 (en) | Beta-hydroxy short to medium chain fatty acid polymer | |
CN115969957B (zh) | 一种炎性肠病复合益生菌制剂及其制备方法 | |
Althubiani et al. | Plant-derived prebiotics and its health benefits | |
CN114931598B (zh) | 一种预防和治疗幽门螺杆菌感染的胃溶缓释片及其制备方法 | |
CN111436608A (zh) | 一种改善肝功能损伤的组合物及其应用 | |
CN115944665A (zh) | 一种改善肠道菌群平衡的益生菌剂及其制备方法和应用 | |
CN115120646A (zh) | 一种平衡肠道菌群的益生菌组合物及其制备方法和应用 | |
CN111066991A (zh) | 一种改善胃肠道功能的复合益生元固体饮料的制备方法 | |
Staka et al. | Impact of oat-based products on human gastrointestinal tract | |
Ashaolu et al. | Prebiotics in vitro digestion by gut microbes, products’ chemistry, and clinical relevance | |
WO2023019461A1 (zh) | 一种改善肝功能损伤的组合物及其应用 | |
Li et al. | The potential role of alfalfa polysaccharides and their sulphated derivatives in the alleviation of obesity | |
CN115500508A (zh) | 一种阻糖减脂组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200724 |